A kind of Enzalutamide soft capsule and preparation method thereof

By adding purified water and mixed solvents with long-chain fatty acid glycerides into the ingredients process of enzalubic acid soft capsules, the problem of poor drug solubility is solved, the production efficiency and product quality stability are improved, and it is suitable for large-scale production.

CN114053243BActive Publication Date: 2024-11-12QILU PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202010778827.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2020-08-05
Publication Date
2024-11-12
Estimated Expiration
2040-08-05

AI Technical Summary

Technical Problem

Enzalumil drug preparations have poor solubility and long dissolution time, which leads to increased process costs and sample quality risks, making it difficult to be suitable for large-scale production.

Method used

In the batching process, purified water is added with long-chain fatty acid glycerides as a mixed solvent for the drug, which significantly shortens the batching time and improves production efficiency. By controlling the moisture content between 2.0% and 5.0%, it ensures the stability of product quality.

Benefits of technology

It significantly improves the production efficiency of enzalubic acid soft capsules, reduces production costs, and ensures the stability of product quality, making it suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0002619465670000061
    Figure BDA0002619465670000061
  • Figure BDA0002619465670000062
    Figure BDA0002619465670000062
  • Figure BDA0002619465670000063
    Figure BDA0002619465670000063
Patent Text Reader

Abstract

The present invention is named as a kind of enzalutamide soft capsule and its preparation method, belonging to the technical field of pharmaceutical preparations. The present invention provides an enzalutamide soft capsule, comprising contents and capsule shells, wherein the contents contain active ingredient enzalutamide and pharmaceutically acceptable pharmaceutical excipients, and enzalutamide accounts for 3.5%-4.5% of the total weight of the contents; the pharmaceutical excipients include long-chain fatty acid glycerides, purified water M and antioxidants, and the amount of purified water M is 0.5%-5.0% of the total weight of the contents. The present invention also provides a preparation method for the above-mentioned pharmaceutical composition. In the batching process of the contents, the present invention adds purified water M and a long-chain fatty acid glyceride solvent to mix as a mixed solvent of the drug, which can significantly shorten the dissolution time of the drug, improve the production efficiency of the enzalutamide soft capsule of the present invention, reduce production costs, and be conducive to industrial production. And the quality of the enzalutamide soft capsule finally prepared is stable and reliable, and the content of related substances meets the requirements.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an enzalutamide soft capsule and a preparation method thereof. Background Art

[0002] Prostate cancer is the most common malignant tumor in men in North America and Europe, and ranks second only to lung cancer in cancer-related deaths. In recent years, the incidence of prostate cancer in my country has shown a significant and sustained increase, and prostate cancer is becoming a urinary system malignancy that seriously affects the health of Chinese men. In the early stages of metastatic prostate cancer, endocrine therapy is the main treatment. Most prostate cancer patients only have a remission period of 18 to 24 months after androgen deprived therapy (ADT), and eventually develop into castration resistant prostate cancer (CRPC). The androgen receptor (AR) pathway plays a key role in the occurrence and progression of prostate cancer, and can even cause cancer cells to continue to grow at the lowest androgen levels. Therefore, the AR signaling pathway is an ideal target for the development of new prostate cancer drugs.

[0003] Enzalutamide (MDV3100, trade name Xtandi) is a second-generation androgen receptor antagonist and a new drug targeting the androgen receptor (AR) signaling pathway. The drug can act on different stages of the androgen receptor signaling pathway, competitively inhibiting the binding of androgens to the receptor, and inhibiting the nuclear translocation of androgen receptors and their interaction with DNA. Enzalutamide showed strong anti-tumor effects and fewer adverse reactions in clinical trials. It was approved for marketing by the US FDA on August 31, 2012, with the indication of metastatic castration-resistant prostate cancer. On September 10, 2014, the FDA supplemented the approval of enzalutamide as a first-line drug for patients with metastatic castration-resistant prostate cancer who have not received chemotherapy. In the same year, the National Institute for Clinical Effectiveness (NICE) of the United Kingdom recommended enzalutamide for the treatment of prostate cancer in its final guidelines.

[0004] Enzalutamide has a good clinical effect in treating castration-resistant prostate cancer, but there are some unresolved technical problems in enzalutamide drug preparations. According to information released by the FDA, enzalutamide belongs to BCS class II, has poor solubility, and takes a long time to dissolve during the preparation process, which increases the process cost. In addition, due to the long dissolution time of enzalutamide during the batching process, it also increases the risk of sample quality, such as decreased drug content, increased related substances, and excessive microorganisms. Summary of the invention

[0005] In view of the deficiencies in the prior art, the present invention provides an enzalutamide soft capsule having simple process, high production efficiency, stable quality and suitable for large-scale production and a preparation method thereof.

[0006] The inventors have found through research that in the batching process, adding purified water and long-chain fatty acid glycerides as a mixed solvent for the drug can significantly shorten the batching time, improve the production efficiency of enzalutamide soft capsules, reduce production costs, and facilitate industrial production.

[0007] In the context of the present invention, the term "content" refers to the substance enclosed in the capsule shell.

[0008] The innovation of the present invention is that enzalutamide is poorly soluble in water, and has low solubility in oil solvents such as long-chain fatty acid glycerides, such as monolinoleic acid glyceride, soybean oil, caprylic acid capric acid mono- and diglycerides, and medium-linked triglycerides, and the dissolution process has certain difficulties. Based on the fact that enzalutamide is poorly soluble in water, purified water should not be introduced in the batching process, but the inventors have found that the batching method of the present invention, that is, adding purified water in the content batching process, can promote the rapid dissolution of the drug in the mixed solvent, and the dissolution rate is greatly improved compared with not adding purified water, thereby improving production efficiency while ensuring product quality. And the enzalutamide soft capsules prepared by the above-mentioned preparation method control the content water content at 2.0%-5.0%, and the product quality is stable.

[0009] The present invention provides an enzalutamide soft capsule, comprising contents and a capsule shell, wherein the contents comprise an active ingredient enzalutamide and pharmaceutically acceptable pharmaceutical excipients, wherein the active ingredient enzalutamide accounts for 3.5%-4.5% of the total weight of the contents. The pharmaceutical excipients comprise long-chain fatty acid glycerides, purified water M and an antioxidant, wherein the amount of the purified water M is 0.5%-5.0% of the total weight of the contents. Preferably, the amount of the purified water M is 1.0%-3.0% of the total weight of the contents.

[0010] The long-chain fatty acid glyceride is selected from one of polyethylene glycol 40, polysorbate 80, caprylic acid capric acid macrogol glyceride or any combination thereof, preferably caprylic acid capric acid macrogol glyceride. The amount of the long-chain fatty acid glyceride is 85%-95% of the total weight of the content.

[0011] The antioxidant is selected from vitamin E, coenzyme Q10, butylated hydroxyanisole, thioglycerol, butylated hydroxytoluene, propyl gallate or any combination thereof, preferably a combination of butylated hydroxyanisole and butylated hydroxytoluene. The amount of the antioxidant is 0.01%-0.1% of the total weight of the content.

[0012] The present invention also provides a method for preparing enzalutamide soft capsules, comprising the following steps:

[0013] (1) uniformly mixing a prescribed amount of long-chain fatty acid glyceride and purified water M to obtain a mixed solvent;

[0014] (2) adding the prescribed amount of enzalutamide and an antioxidant to the mixed solvent obtained in step (1), stirring to dissolve, and after the enzalutamide is completely dissolved, vacuum degassing to obtain a content containing enzalutamide;

[0015] (3) Add the prescribed amount of plasticizer and purified water N to a glue tank and heat to 60-85° C., stir and dissolve until the solution is clear, add a sunscreen and stir until it is evenly dispersed, add gelatin and stir and dissolve until there are no obvious particles in the glue solution, vacuum degas until there are no bubbles floating in the glue solution for at least 30 minutes, and let it stand for 2-20 hours to obtain a standby glue solution;

[0016] (4) pressing the enzalutamide-containing content obtained in step (2) and the reserved glue solution obtained in step (3) into a soft capsule filling machine to obtain a primary soft capsule;

[0017] (5) shaping and drying the preliminary soft capsule obtained in step (4) to obtain the final product, enzalutamide soft capsule.

[0018] The stirring and dissolving in step (2) is preferably carried out at 35°C-45°C.

[0019] In some preferred embodiments, the moisture content of the first soft capsule obtained in step (4) is controlled to be 2.0%-5.0% of the total weight of the contents after the drying step in step (5). Further preferably, the moisture content of the first soft capsule obtained in step (4) is controlled to be 3.5%-4.5% of the total weight of the contents after the drying step in step (5).

[0020] In some embodiments, the plasticizer in step (3) is selected from one of glycerol, sorbitol, sorbitan, maltitol, mannitol, propylene glycol, polyethylene glycol or any combination thereof. In some preferred embodiments, the plasticizer in step (3) is selected from a mixture of glycerol and sorbitan. The amount of the plasticizer is 20%-40% of the weight of the capsule shell formulation.

[0021] In some embodiments, the sunscreen in step (3) is titanium dioxide. The amount of the sunscreen is 0.2%-2.0% of the weight of the capsule shell formula. In some preferred embodiments, the amount of the sunscreen is 0.2%-1.0% of the weight of the capsule shell formula.

[0022] In some embodiments, the amount of purified water N is 25%-45% of the weight of the bladder shell formula. In some preferred embodiments, the amount of purified water N is 30%-40% of the weight of the bladder shell formula. In other preferred embodiments, the amount of purified water N is 30%-35% of the weight of the bladder shell formula.

[0023] In some preferred embodiments, nitrogen protection is used throughout the process of preparing the contents in step (2) and step (4) to further improve the stability of the enzalutamide soft capsules.

[0024] The beneficial effects of the present invention are:

[0025] In the process of preparing the contents, adding purified water M and mixing with a long-chain fatty acid glyceride solvent as a mixed solvent for the drug can significantly shorten the dissolution time of the drug, improve the production efficiency of the enzalutamide soft capsule of the present invention, reduce the production cost, and facilitate industrial production.

[0026] In addition, after the drying step, the moisture content of the enzalutamide soft capsule is controlled within a certain range, such as 2.0%-5.0%, especially 3.5%-4.5%, which can effectively ensure the stability of the quality of the enzalutamide soft capsule product. DETAILED DESCRIPTION

[0027] The present invention will be further described below in conjunction with specific examples. Before describing the present invention in detail below, it should be understood that the present invention is not limited to the specific methodology, scheme and reagent described herein, and simple improvements to the present invention under the premise of the technical solution of the present invention all belong to the protection scope of the present invention. It should also be understood that the terms used herein are only for describing specific embodiments, and are not intended to limit the scope of the present invention. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those of ordinary skill in the art to which the present invention belongs.

[0028] Examples 1-4 and Comparative Example 1: Comparison of drug dissolution time under different dosages of purified water M

[0029] The prescription and composition of the samples of Examples 1-4 and Comparative Example 1 are shown in Table 1.

[0030] Table 1 Contents of Examples 1-4 and Comparative Example 1

[0031] Components Example 1 Example 2 Example 3 Example 4 Comparative Example 1 Enzalutamide 40g 40g 40g 40g 40g Caprylic / capric macrogol glycerides 905.81g 905.81g 905.81g 905.81g 905.81g Butylated Hydroxytoluene 0.095g 0.095g 0.095g 0.095g 0.095g Butylated Hydroxyanisole 0.095g 0.095g 0.095g 0.095g 0.095g Purified water 9.0g 12g 18.1g 27.2g /

[0032] Preparation method:

[0033] (1) uniformly mixing a prescribed amount of caprylic acid capric acid macrogol glyceride with different amounts of purified water M to obtain a mixed solvent;

[0034] (2) Adding a prescribed amount of enzalutamide and an antioxidant (a mixture of butylated hydroxytoluene and butylated hydroxyanisole) to the mixed solvent obtained in step (1), stirring and dissolving at 45° C., and after the enzalutamide is completely dissolved, vacuum degassing is performed to obtain a content containing enzalutamide.

[0035] According to the prescriptions of Examples 1-4 and Comparative Example 1, the corresponding solutions were prepared, and the dissolution time of the raw materials and the quality of the contents during the preparation process were investigated. The relevant substances were determined by high performance liquid chromatography (HPLC). The results are shown in Table 2. The chemical name of impurity DO is 4-[3-(4-cyano-3-trifluoromethylphenyl)-5,5-dimethyl-2,4-dioxo-1-imidazolinyl]-2-fluoro-N-methylbenzamide, and the molecular formula is C 21 H 16 F4N4O3, molecular weight is 448.37, structural formula is as follows:

[0036]

[0037] Table 2 Comparison of batching time and content mass of Examples 1-4 and Comparative Example 1

[0038]

[0039] The results show that, compared with the comparative example 1, the drug dissolution rate of the examples 1-4 in the present invention is significantly accelerated during the batching process. This indicates that the introduction of purified water in the preparation process is beneficial to accelerate the batching speed. In addition, no significant changes were observed in the related substances, indicating that the introduction of purified water M can ensure that the product quality remains unchanged and is suitable for large-scale production.

[0040] Examples 5-8 and Comparative Example 2: Saturated Solubility Experiment of Enzalutamide in Mixed Solvents with Different Contents of Purified Water M

[0041] Based on the above experimental results, the saturated solubility of enzalutamide in solvents with different water contents was detected to prepare Examples 5-8 and Comparative Example 2. The results are shown in Table 3.

[0042] Table 3 Statistics of solubility results of Examples 5-8 and Comparative Example 2

[0043]

[0044] The results show that in mixed solvents made by adding different amounts of purified water, within a certain proportion range, the higher the content of purified water, the greater the solubility of enzalutamide.

[0045] Examples 9-12 and reference preparations: Comparison of stability and dissolution behavior of enzalutamide soft capsules

[0046] The preparation of the standby glue required for the capsule shell, the standby glue formula is shown in Table 4:

[0047] Table 4 Prescription of the spare glue solution for capsule shell

[0048] Components Prescription amount gelatin 6.0kg Sorbitol liquid 1.2kg glycerin 3.0kg Titanium Dioxide 71.37g Purified water 4.9kg

[0049] Preparation of standby glue solution: add the prescribed amount of glycerin and dehydrated sorbitol solution and purified water N into a glue tank and heat to 70°C, stir and dissolve until the solution is clear, add titanium dioxide and stir until it is evenly dispersed, add gelatin and stir and dissolve until there are no obvious particles in the glue solution, vacuum degas until there are no bubbles floating in the glue solution for at least 30 minutes, and let it stand for 2 hours to obtain the standby glue solution;

[0050] Preparation of enzalutamide soft capsules: The enzalutamide-containing contents obtained in Examples 1-4 were respectively pressed into shape using the above-mentioned reserved glue solution using a soft capsule filling machine to obtain a preliminary soft capsule; the preliminary soft capsule was shaped and dried to obtain a final product, enzalutamide soft capsule, and the final products obtained corresponded to Examples 9-12 respectively.

[0051] The final product of Example 9-12, Enzalutamide soft capsules, was packaged in aluminum plastic. The reference preparation Xtandi was the Enzalutamide soft capsules developed by Astellas. The products of Example 9-12 and the reference preparation were placed under accelerated conditions (40°C, 75±5%RH) at the same time, and samples were taken at 0 days and 6 months, respectively, to investigate the dissolution curves of related substances, water content and 0.1 mol / L hydrochloric acid solution. The dissolution was determined by high performance liquid chromatography (HPLC), and the water content was determined by Karl Fischer method. The results are shown in Table 5.

[0052] Table 5 Quality comparison of Examples 9-12 and reference preparations

[0053]

[0054] In addition, the dissolution of Examples 9-12 and the reference preparation is shown in Table 6:

[0055] Table 6 Comparison of dissolution curves of Examples 7-9 and reference preparations

[0056]

[0057] The results show that there is no significant change in the related substances in Examples 9-12 of the present invention compared with the reference preparation, and the dissolution behavior is consistent. Different amounts of purified water M are added to the contents of Examples 9-12, and the soft capsules are prepared and dried. It is found that the water content in the contents of the soft capsules of Examples 7-9 is basically the same, and the quality of the final product is not different due to the different amounts of purified water M added to the contents. That is, adding a small amount of purified water M when preparing the contents can effectively improve the dissolution rate of the raw materials, and the quality of the enzalutamide soft capsule samples prepared by this formulation method is stable.

[0058] Examples 13-15: Investigating the effects of different drying times on soft capsules

[0059] Soft capsule samples were prepared according to the prescription in Table 7. Different drying times were used in the process of preparing the contents, resulting in different percentages of moisture in the contents. The enzalutamide soft capsules finally obtained were respectively designated as Examples 13-15, as shown in Table 8.

[0060] Table 7 Example prescription

[0061]

[0062] Table 8 Examples 13-15

[0063] Example Drying time Contents moisture % Embodiment 13 About 85h 4.5 Embodiment 14 About 110h 3.9 Embodiment 15 About 140h 3.5

[0064] The aluminum-plastic packaging of Examples 13-15 was placed under accelerated conditions (40°C, 75±5% RH), and samples were taken at 0 day and 6 months respectively to examine the relevant substances, the moisture content and the 30-minute solubility in 0.1 mol / l hydrochloric acid solution. The results are shown in Table 9.

[0065] Table 9 Statistics of test results of Examples 13-15

[0066]

[0067] The results show that the quality of the enzalutamide soft capsules made from different moisture contents is stable, and the moisture in the contents and the capsule shell can migrate to each other during storage to reach a certain balance. Therefore, controlling the moisture content of the contents within a certain range has no effect on the product quality, and the product quality is stable.

Claims

1. An enzalutamide soft capsule, comprising contents and a capsule shell, wherein the contents comprise an active ingredient enzalutamide and a pharmaceutically acceptable pharmaceutical excipient, wherein the active ingredient enzalutamide accounts for 3.5%-4.5% of the total weight of the contents; the pharmaceutical excipients comprise long-chain fatty acid glycerides, purified water and an antioxidant, wherein the amount of the purified water is 0.5%-5.0% of the total weight of the contents; the long-chain fatty acid glycerides are selected from caprylic acid capric acid macrogol glycerides, and the amount thereof is 85%-95% of the total weight of the contents; the antioxidant is selected from a combination of butylated hydroxyanisole and butylated hydroxytoluene, and the amount thereof is 0.01%-0.1% of the total weight of the contents.

2. The enzalutamide soft capsule according to claim 1, wherein the amount of purified water is 1.0%-3.0% of the total weight of the contents.

3. The method for preparing the enzalutamide soft capsule according to claim 1 or 2, comprising the following steps: (1) uniformly mixing a prescribed amount of long-chain fatty acid glyceride and purified water to obtain a mixed solvent; (2) adding the prescribed amount of enzalutamide and antioxidant to the mixed solvent obtained in step (1), stirring to dissolve, and after the enzalutamide is completely dissolved, vacuum degassing to obtain a content containing enzalutamide; (3) Add the prescribed amount of plasticizer and purified water to the glue tank and heat to 60-85°C, stir and dissolve until the solution is clear, add the sunscreen and stir until it is evenly dispersed, add gelatin and stir and dissolve until there are no obvious particles in the glue solution, vacuum degas until there are no bubbles floating in the glue solution for at least 30 minutes, and let it stand for 2-20 hours to obtain the standby glue solution; (4) pressing the enzalutamide-containing content obtained in step (2) and the reserved gelatin solution obtained in step (3) into a soft capsule filling machine to obtain a primary soft capsule; (5) shaping and drying the preliminary soft capsules obtained in step (4) to obtain the final product, enzalutamide soft capsules.

4. The preparation method according to claim 3, wherein the stirring and dissolving in step (2) is carried out at 35°C-45°C.

5. The preparation method according to claim 3, wherein the moisture content of the contents of the soft capsule after the drying step in step (5) is controlled to be 2.0%-5.0% of the total weight of the contents.

6. The preparation method according to claim 3, wherein the moisture content of the contents of the soft capsule after the drying step in step (5) is controlled to be 3.5%-4.5% of the total weight of the contents.

7. The preparation method according to any one of claims 3, wherein the plasticizer in step (3) is selected from a mixture of glycerol and sorbitan; the amount of the plasticizer is 20%-40% of the weight of the capsule shell formula.

8. The preparation method according to claim 3, wherein the sunscreen in step (3) is titanium dioxide; the amount of the sunscreen is 0.2%-2.0% of the weight of the capsule shell formula.

9. The preparation method according to claim 8, wherein the amount of the sunscreen agent is 0.2%-1.0% of the weight of the capsule shell.

10. The preparation method according to claim 3, wherein the amount of purified water used in step (3) accounts for 25%-45% of the weight of the capsule shell formula.

11. The preparation method according to claim 3, wherein the amount of purified water used in step (3) accounts for 30%-40% of the weight of the capsule shell formula.

12. The preparation method according to claim 3, wherein the amount of purified water used in step (3) accounts for 30%-35% of the weight of the capsule shell formula.

13. The preparation method according to claim 3, wherein nitrogen protection is used throughout the steps (2) and (4) of preparing the contents.